Retatrutide is a new pharmaceutical in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in research studies. By boosting these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ultimately contributes to significant reduction in body mass.